Abstract | BACKGROUND: METHODS: A Phase II clinical trial of single-agent SV given at a dose of 2.0 mg/m2 every 2 weeks was conducted in patients with recurrent or refractory ALL. Approximately half of the 16 patients who received SV had a first CR duration of less than 1 year, 19% had failed standard induction chemotherapy, and 50% had Philadelphia chromosome-positive disease. SV was the first salvage attempt in 69% of the patients. RESULTS: The overall response rate in the 14 evaluable patients was 14% (1 CR and 1 partial response). Five patients (36%) had transient reductions in bone marrow leukemia infiltrate with subsequent regrowth of the leukemia between SV infusions. Toxicity with limited treatment (median number of doses was two; range, one to five doses) was minimal with expected peripheral neuropathy. CONCLUSIONS: Further study of SV in patients with ALL is warranted. A Phase I-II clinical trial of weekly SV with pulse dexamethasone currently is ongoing.
|
Authors | Deborah A Thomas, Andreas H Sarris, Jorge Cortes, Stefan Faderl, Susan O'Brien, Francis J Giles, Guillermo Garcia-Manero, Maria A Rodriguez, Fernando Cabanillas, Hagop Kantarjian |
Journal | Cancer
(Cancer)
Vol. 106
Issue 1
Pg. 120-7
(Jan 01 2006)
ISSN: 0008-543X [Print] United States |
PMID | 16331634
(Publication Type: Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright 2005 American Cancer Society. |
Chemical References |
- Antineoplastic Agents, Phytogenic
- Liposomes
- Sphingomyelins
- Vincristine
|
Topics |
- Adolescent
- Adult
- Aged
- Antineoplastic Agents, Phytogenic
(administration & dosage, adverse effects, therapeutic use)
- Drug Administration Schedule
- Drug Resistance, Neoplasm
- Humans
- Liposomes
- Middle Aged
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
(drug therapy, pathology)
- Recurrence
- Salvage Therapy
- Sphingomyelins
- Vincristine
(administration & dosage, adverse effects, therapeutic use)
|